AUM Biosciences publication of role of PIM/PI3K/mTOR inhibition in treatment of NSCLC

AUM Biosciences, a clinical stage oncology focused biotech developing innovative therapies for undruggable intracellular targets, announces the publication “Co-targeting PIM Kinase and PI3K/mTOR in NSCLC” in Cancers by Dr Kathy Gately1 and her colleagues at the Trinity Translational Medicine Institute, St. James Hospital, Dublin, Ireland.

Dr. Harish Dave, Chief Medical Officer at AUM Biosciences noted “This is a seminal study of the importance of PIM kinases in NSCLC. Inhibition of PI3K/mTOR and PIM kinases by IBL-301 was effective at inhibiting co-regulator c-Myc, an undruggable target. PI3K/mTOR resistant cell lines have activation of PIM kinase and c-Myc. IBL-301 co-targeting of both PIM and PI3K/mTOR pathways has the potential to be more efficacious and provide a durable response in patients with an activated PIM kinase and/or PI3K/mTOR pathway.” IBL-301 is a member of the IBL-300 family of molecules. This family of molecules are rationally designed multi-kinase inhibitors targeting PI3K, PIM and mTOR and are licensed to AUM Biosciences.

About PI3K/mTOR

The PI3K/mTOR pathway is dysregulated in almost all human cancers, including lung cancer, breast cancer, colorectal cancer, and hematologic malignancies. This emphasizes the centrality of targeting this pathway when treating cancer. PIM kinases share several downstream signalling steps with PI3K/mTOR and represent a bypass mechanism. Suppression of PI3K/mTOR and PIM together has the potential for both greater efficacy and may prevent or suppress resistance.

IBL-300/AUM300 series

This series of molecules represent a first-in-class group of rationally designed, multi-targeted multi-kinase inhibitors with high potency activity against PI3K/mTOR and PIM. AUM302 is being developed by AUM Biosciences for multiple solid tumor indications.

Read the full publication HERE

About AUM Biosciences

AUM Biosciences is a global clinical stage biotech company, focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. The management team has an extensive track record of selecting distinctive early stage assets, successfully exiting virtual biotech models, and have contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM was founded to enable a holistic strategy for drug development and improving the probability of success with a focus on synergism, sustainability and scalability.

Reference

1) 1. Moore, G.; Lightner, C.; Elbai, S.; Brady, L.; Nicholson, S.; Ryan, R.; O’Sullivan, K.E.; O’Byrne, K.J.; Blanco-Aparicio, C.; Cuffe, S.; O’Neill, M.; Heavey, S.; Finn, S.P.; Gately, K. Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC. Cancers 2021, 13, 2139. https://doi.org/10.3390/cancers13092139